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In	recent	years,	the	use	of	newly	synthesised	small	
molecules,	combinations	of	therapeutic	modalities	or	
naturally	occurring	agents	to	prevent	the	development	
or	recurrence	of	cancer	has	become	widely	accepted	
[1–5].	Nigella sativa Linn,	commonly	known	as	black	
seed	or	black	cumin,	is	an	annual	plant	belonging	to	the	
Ranunculaceae	family.	The	herb	has	been	traditionally	
used	in	the	Indian	subcontinent,	Arabian	countries	and	
Europe	 for	culinary	and	medicinal	purposes	 [6–7].	
Nigella sativa seeds	contain	diverse	but	well-charac-
terized	chemical	components,	which	include	essential	
oils,	proteins,	alkaloids	and	saponins	[8–9].
The	chemotherapeutic	and	chemoprotective	ef-
fects	of	N. sativa	extract	may	be	due	to	quinones	that	
include	thymoquinone	(TQ),	dithymoquinone	(DIM)	and	
thymohydroquinone	(THQ)	that	are	present	in	the	oil	of	
this	seed.	TQ	suppresses	benzo(a)pyrene	(BP)-induced	
forestomach	tumor	formation	[10]	and	tumor	formation	
in	DMBA-initiated,	TPA-promoted	mouse	skin	[11],	as	
well	as	a	chemopreventive	agent	at	the	early	stage	of	skin	
tumorigenesis.	The	antineoplastic	activity	of	TQ	may	be	
attributed	to	its	inhibitory	effects	on	cancer	cell	growth	
and	its	capability	of	inducing	apoptosis	in	cancer	cells	
[12].	The	TQ	enhances	the	antitumor	activity	of	cisplatin	
and	ifosfamide	[13],	and	improves	their	therapeutic	index	
[14].	Among	its	wide-spectrum	pharmacologic	activities,	
TQ	has	antineoplastic	activity	against	various	tumor	cells	
[11,	15–16].	DIM	also	contributes	to	the	chemotherapeu-
tic	effects	of	N. sativa.	In vitro studies	indicate	that	DIM	is	
equally	as	cytotoxic	as	TQ	to	several	parental	human	tu-
mor	cell	lines	and	their	corresponding	multidrug	resistant	
(MDR)	variants	[16].	TQ	and	THQ	exhibit	limited	specific	
inhibitory	effect	on	COX-2	[17].	Although	the	antitumor	
activity	of	TQ	is	relatively	well	characterised	in vitro	the	
data	about	its	antitumor	activity	in vivo	are	very	limited.	
Till	today	data	about	in vitro	and	in vivo	antitumor	activi-
ties	of	thymohydroquinone	are	still	unknown.	Hence,	the	
purpose	of	this	study	was	to	explore	in vitro	and	in vivo	
antitumor	activities	of	TQ	and	THQ.
Materials and Methods
Chemistry.	 TQ	and	THQ	were	prepared	 in	our	
laboratory	by	the	methods	of	Kremers	et	al.	[18]	and	
Stolow	et	al.	[19].	NMR	spectroscopy	(Bruker	AMX-
400)	confirmed	the	structures	of	compounds.
TQ:	1H	NMR	(CDCl3,	400	MHz):	δ	(multiplicity,	num-
ber	of	protons,	assignment)	1.13-1.23	(d,	6H,	2xCH3),	
2.18	(s,	3H,	CH3),	3.12-3.15	(m,	1H,	CH),	4.37	(b,	2H,	
OH),	6.55	(s,	1H,	iPr=CH-),	6.64	(s,	1H,	Me=CH-).
13C	NMR	(CDCl3,	100	MHz):	15.38,	21.41,	26.45,	
77.15,	130.37,	133.85,	145.29,	154.96,	187.45,	188.64.
THQ:	 1H	NMR	 (CDCl3,	 400	MHz):	 δ	 1.13-1.23	
(d,	6H,	2xCH3),	2.18	 (s,	3H,	CH3),	3.12-3.15	15	 (m,	
1H,	CH),	4.37	(b,	2H,	OH),	6.55	(s,	1H,	iPr=CH-),	6.64	
(s,	1H,	Me=CH-).
13C	NMR	(CDCl3,	100	MHz):	15.39,	22.68,	26.85,	
77.15,	113.03,	117.69,	121.61,	133.10,	146.27,	147.72.
Cell lines and the evaluation of cytotoxicity.	In	
the	 in vitro	experiments	L929	mouse	ﬁbroblasts	and	
two	 tumor	cell	 lines	 (SCC	VII	and	FsaR)	were	used.	
Mentioned	cell	lines	belong	to	the	same	genetic	back-
ground,	and	 their	ability	 to	produce	solid	 tumors	 in	
syngeneic	mice	make	them	a	very	good	model	for	an-
titumor	activity	investigations	of	substances	in vitro	and	
in vivo.	All	cell	lines	were	grown	in	a	RPMI	1640	medium	
supplemented	with	10%	foetal	calf	serum	(FCS)	 in	a	
humidiﬁed	atmosphere	of	5%	CO2	in	air	at	37	°C.	
For	each	experiment,	L929,	SCC	VII	and	FsaR	cells	
were	harvested	and	plated	on	96-well	microtiter	plates	
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(100	µl/well)	at	an	initial	concentration	of	approximately	
1	x	104	cells/100	µl.	When	the	cells	reached	conﬂuence	
(usually	24	h),	 the	old	cultured	medium	was	replaced	
with	a	fresh	one	and	than	TQ	or	THQ	were	added	to	the	
final	concentrations	of	0.1	or	0.01	mg	ml-1.	Control	cells	
were	incubated	in	a	medium	without	addition	of	tested	
substances.	The	cells	were	incubated	for	24	h,	and	then	
the	treated	and	untreated	cells	were	ﬁxed	by	the	addi-
tion	of	1%	glutaraldehyde	solution	for	15	min,	washed	
with	deionised	water	and	dried	in	air.	After	that	the	cells	
were	stained	with	0.1%	crystal	violet	 for	20	min,	 then	
extensively	washed	with	deionised	water	and	allowed	
to	dry	overnight.	The	cells	thus	ﬁxed	were	visualized	us-
ing	an	inverted	inverse	microscope	(Zeiss,	Axiovert	35),	
equipped	with	the	digital	microscopy	camera	processed	
with	the	Viewﬁnder	program.	To	obtain	quantitative	cyto-
toxicity	data,	the	dye	was	extracted	from	the	cells	using	
a	0.2%	solution	of	Triton	X-100,	and	then	absorbance	
was	read	at	595	nm	(Anthos	Microplate	Reader	HT3).	
Absorbance	at	the	wave	length	of	590	nm	is	proportional	
to	the	number	of	surviving	cells.	Each	experiment	was	
made	in	quadruplicate	and	repeated	three	times.	In	ad-
dition	to	the	cell	growth	 inhibition	(CGI)	ratio	was	also	
calculated	from	the	absorbance	values	by	the	formula:	
CGI	=	(C-T/C)	x	100,	where	C	is	mean	absorbance	value	
of	untreated	(control)	cells	and	T	 is	mean	absorbance	
value	of	treated	cells.
Experimental animals.	C3HHf/Bu	Zgr/Hr	male	mice	
were	used.	Animals	were	3	months	old	at	the	beginning	of	
the	experiments.	Eight	mice	were	used	in	each	group	per	
experiment.	Each	experiment	was	repeated	twice.	Mice	
were	obtained	from	Rudjer	Boskovic	Institute’s	breeding	
colony.	During	experimental	period	4	animals	were	kept	
per	cage.	Bottom	of	cage	was	covered	with	sawdust	(All-
span®,	Germany).	Standard	food	for	laboratory	mice	(4	
RF	21	GLP	Mmucedola	srl,	Italy)	was	used.	All	animals	had	
access	to	food	and	water	ad	libitum.	Animals	were	kept	
in	conventional	circumstances:	light/dark	rhythms	12/12	
h,	temperature	22	°C,	and	humidity	55%.	All	experiments	
were	performed	according	to	the	ILAR	Guide	for	the	Care	
and	Use	of	Laboratory	Animals,	Council	Directive	(86/609/
EEC)	and	Croatian	animal	welfare	law	(NN	19/99).
tumor models.	For	 in vivo	 antitumor	efficiency	
evaluation	of	new	compounds	two	standard	murine	tumor	
models	(fibrosarcoma	(FsaR)	and	squamous	cell	carci-
noma	(SCC	VII))	were	used.	Both	tumor	models	belong	
to	the	same	genetic	background	(originated	from	the	C3H	
mice	strain).	SCC	VII	cells	belong	to	the	epithelial	tumor	
of	ectodermal	origin,	whereas	FsaR	cell	line	is	of	meso-
dermal	origin,	so	that	we	can	compare	the	tumors	with	
the	same	genetic	background	and	different	histogenesis.	
Fibrosarcoma	(FsaR),	and	squamous	cell	carcinoma	(SCC	
VII)	had	been	maintained	in	C3HHf/Bu	Zgr/Hr	mice.	For	
the	experimental	purpose	tumor	cells	(5	x	105	in	100	µl	of	
RPMI)	were	transplanted	subcutaneously	into	the	thigh	
of	the	right	leg	using	a	tuberculin	syringe	and	a	25-gauge	
needle.	The	viability	of	the	cells	was	determined	by	Trypan	
blue	dye	exclusion	test	and	it	was	over	95%.
test substances and dosage.	All	substances	were	
stored	at	+4	°C	and	freshly	dissolved	in	distilled	water	im-
mediately	prior	to	injection	(for	each	application).	Three	
days	after	tumor	cells	inoculation	TQ	or	THQ	(5	mg/kg	
in	a	volume	of	100	µl)	were	injected	intratumourally	for	
the	first	time.	The	application	was	repeated	on	days	4,	
5	and	11	following	tumor	cells	inoculation,	so	that	the	
total	received	dose	was	20	mg/kg.	The	chosen	dose	is	
one	half	of	LD50	of	more	toxic	substance	(thymoquinone)	
applied	i.p.	as	a	single	dose	therapy	[20].	The	control	
group	received	on	same	days	100	µl	of	distilled	water.	
tumor response.	Tumor	response	(endpoint)	was	
studied	as	a	tumor	growth	delay	study	[21].	In	order	
to	get	a	tumor	volume,	three	orthogonal	diameters	(A,	
B	and	C)	of	a	growing	tumor	were	measured	with	cal-
liper	on	days	8,	11,	14,	17	and	21	after	the	tumor	cell	
injection.	The	tumor	volume	(V)	was	calculated	by	the	
formula	V	=	ABCπ/6.	Antitumor	effect	was	evaluated	by	
a	comparison	of	a	tumor	growth	between	treated	and	
untreated	(control)	groups.	The	relative	tumor	growth	
(given	in	%	of	control)	was	calculated	by	the	formula:	
RTG	=	(T/C)	x	100,	where	C	is	mean	tumor	volume	of	
control	(untreated)	group	and	T	is	mean	tumor	volume	
of	treated	groups.	Tumor	growth	inhibition	(TGI)	was	
calculated	from	the	RGI	by	formula	100-RGI	%.	
Statistical analysis.	 Statistical	 analyses	were	
conducted	by	 “Statistica	 for	Windows	4.0”	—	Stats	
soft	Inc.	USA	1993.	Obtained	data	were	tested	firstly	
by	Shapiro-Wilks	W-test,	Levene’s	test	for	normality	
and	homogeneity	of	variance,	respectively.	After	that	a	
one-way	ANOVA	test	was	applied	to	assess	the	overall	
difference	among	experimental	groups	and	if	ANOVA	
was	significant	 than	differences	among	 the	means	
were	assessed	by	the	Tukey	multiple	comparison	test.	
Statistical	significance	was	defined	as	p	<	0.05.
results
Cytotoxic assay. The	effect	of	thymoquinone	and	
thymohydroquinone	was	tested	on	normal	fibroblasts	cell	
line	(L929)	and	two	tumor	cell	lines	(SCC	VII	and	FsaR).	
The	effects	of	therapy	with	TQ	and	THQ	on	cells	growth	
are	shown	on	photomicrographs	(Fig.	1).	Data	show	that	
control	cells	were	of	high	density	with	well-defined	mor-
phological	characteristics	of	certain	cultures.	24	h	after	
addition	of	TQ	or	THQ	noticeable	changes	were	visible	
in	the	morphology	and	density	of	treated	cells.	Almost	
all	treated	cells	became	rounded	and	their	number	was	
reduced	in	comparison	with	the	control	cell	culture.	In	
order	 to	quantify	 the	toxicity	of	TQ	and	THQ	a	crystal	
violet	assay	was	performed.	The	cytotoxic	effects	of	
0.01	and	0.1	mg/ml	of	TQ	and	THQ	on	cells	growth	are	
shown	in	Fig.	2.	In	the	higher	concentration	(0.1	mg/ml)	
both	tested	substances	exhibited	statistically	significant	
cytotoxic	activity	against	tumor	cells	(~	87	and	92%	for	
SCC	VII	and	FsaR	cells,	respectively,	p	<	0.001).	The	cy-
totoxic	activity	was	dose	dependent	and	it	was	up	to	44%	
for	lower	dose	(0.01	mg/ml)	and	up	to	92%	for	higher	
dose	(0.1	mg/ml)	of	TQ	against	tumor	cell	lines	.	The	an-
tiproliferative	ability	of	THQ	was	up	to	17%	for	lower	dose	
(0.01	mg/ml)	and	up	to	92%	for	higher	dose	(0.1	mg/ml)	
against	tumor	cell	lines.	The	results	obtained	with	the	use	
of	“lower”	dose	of	TQ	were	statistically	significantly	better	
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than	those	obtained	with	the	use	of	“lower”	dose	of	THQ.	
The	effect	of	“lower”	doses	of	TQ	or	THQ	against	normal	
mice	fibroblasts	(L929)	was	very	similar	(21–57%)	to	the	
antiproliferative	effects	against	tumor	cell	lines.	On	the	
other	hand	the	antitumor	effect	of	“higher”	doses	of	TQ	or	
THQ	was	cell	specific	and	it	was	statistically	much	more	
expressed	against	tumor	cell	(between	86%	and	92%)	
than	against	normal	fibroblasts	(62–63%).
Antitumor activity evaluation in vivo.	The	goal	
of	the	in vivo	experiments	was	to	determine	antitumor	
activity	of	TQ	and	THQ	on	two	different	murine	tumor	
models	(squamous	cell	carcinoma	(SCC	VII)	and	fibro-
sarcoma	(FsaR)).	From	the	Fig.	2,	in	which	results	of	
therapy	with	TQ	and	THQ	are	shown,	it	could	be	seen	
that	both	used	substances	exert	very	good	antitumor	
activity	against	SCC	VII	and	FsaR.	The	TGI	value	reached	
with	the	use	of	TQ	against	SCC	VII	was	up	to	52%	and	
up	to	43%	against	FsaR.	Therapeutic	effect	(TGI	value)	
achieved	with	the	use	of	THQ	was	up	to	49%	against	
SCC	VII	and	up	to	33%	against	FsaR.	Statistically	sig-
nificant	difference	in	antitumor	activity	in vivo	between	
TQ	and	THQ	has	not	been	found	in	this	study.
discussion
Thymoquinone	is	a	promising	compound	with	significant	
in vitro	and	in vivo	antitumor	activities	against	different	tumor	
fig. 1. Photomicrographs	of	fixed	and	crystal	violet	stained	control	and	treated	cells	24	h	after	the	addition	of	0.1	and	0.01	mg	ml-1	
of	thymoquinone	(TQ)	or	thymohydroquinone	(THQ)
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models	[16,	22,	23].	However	its	mechanism(s)	of	action	
is	still	unknown.	The	present	knowledge	about	antitumor	
activity	of	thymohydroquinone	is	very	limited	and	till	today	
there	is	no	data	about	antitumor	activity	of	THQ	in vivo.	This	
study	was	undertaken	to	demonstrate	the	antitumor	effects	
of	TQ	and	THQ	in vitro	and	in vivo	and	revealed	that	both	
substances	(TQ	and	THQ)	exhibited	good	antiproliferative	
activity	against	tumor	cells	in vitro	which	is	in	agreement	
with	literature	findings	[11,	15,	16,	22,	23].	Furthermore	it	
shows	that	antiproliferative	activity	of	TQ	and	THQ	is	dose	
dependent	and	more	pronounced	towards	tumor	cell	lines	
in vitro.	Similar	observation	of	TQ	inhibiting	activity	against	
human	colon	cancer	cells	(HTC-116)	was	observed	pointing	
to	the	involvement	of	p53	dependent	mechanisms	[24].	
These	results	as	well	as	our	presented	results	 indicate	
that	TQ	triggers	apoptosis	in	a	dose	dependent	manner.	
Apoptosis	induction	by	TQ	was	associated	with	several	fold	
increase	in	mRNA	expression	of	p53	and	the	downstream	
p53	target	gene,	p21WAF1	(oedema).	A	marked	increase	
in	p53	and	p21WAF1	protein	level	and	a	significant	inhibition	
of	anti-apoptotic	Bcdl-2	protein	were	found	in	TQ	treated	
cell	cultures.	However,	p53-null	HCT-116	cells	were	less	
sensitive	to	TQ-induced	growth	arrest	and	apoptosis	[24]	
what	correspond	to	the	reaction	of	FsaR	cells	(p53	wild	
type	is	less	expressed)	[25].	The	role	of	p53	in	TQ	apoptotic	
action	is	supported	by	the	data	from	literature	pointing	that	
co-cultivation	of	TQ	and	pifithrin-alpha,	a	specific	inhibitor	
of	p53,	resulted	in	Bcl-2,	p53	and	p21WAF1	restored	to	
untreated	control	levels.	Further,	THQ	in	a	lower	dose	used	
was	less	effective	than	TQ	against	fibroblast	and	carcinoma	
cells	what	might	correspond	to	its	less	pronounced	toxic-
ity	in vivo,	and	there	are	no	reports	in	literature	about	that	
compound’s	antitumor	action.	Possible	action	of	thymoqui-
nones	on	tumor	angiogenesis	is	of	further	interest,	too.	An-
titumor	activity	of	TQ	and	THQ	against	used	murine	tumors	
in vivo was	very	promising,	especially	for	THQ.	Optimistic	
expectations	are	based	on	the	fact	that	antitumor	activity	
of	THQ	was	as	good	as	antitumor	activity	of	TQ	regardless	
of	fact	that	used	dose	of	THQ	was	two	times	less	toxic	than	
used	dose	of	TQ	(less	than	¼LD50	of	THQ	versus	½LD50	of	
TQ)	[20].	The	present	study	shows	that	the	antiproliferative	
activity	of	tested	substances	is	dose	dependent	and	the	
future	expectations	were	put	on	even	better	therapeutic	
results	for	THQ	with	further	dose	elevation.
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fig. 3. Effects	of	application	of	TQ	or	THQ	on	the	growth	of	mouse	
carcinoma	SCC	VII	(a)	and	fibrosarcoma	Fsar	(b).	The	asterisk	(*)	in-
dicates	statistically	significant	difference	(p	<	0.05)	in	activity	between	
treated	and	control	group.	The	open	circle	(o)	indicate	statistically	
significant	difference	(p	<	0.05)	between	tested	substances
fig. 2. Cytotoxic	effects	of	0.01	and	0.1	mg/ml	of	thymoquinone	
(TQ)	and	thymohydroquinone	(THQ)	on	mouse	fibroblast	L929	(a),	
squamous	cell	carcinoma	SCC	VII	(b)	and	fibrosarcoma	FsaR	(c)	
cell	lines	as	evaluated	by	the	crystal	violet	cytotoxic	assay.	Inside	of	
each	of	the	treated	group	bars	the	values	of	the	cell	growth	inhibition	
(CGI	%)	was	also	presented.	The	asterisk	(*)	indicates	statistically	
significant	difference	(p	<	0.01)	in	activity	between	same	concentra-
tions	of	TQ	and	THQ	on	particular	cell	lines.	Small	letters	a,	b,	c	(for	
each	tested	compound	on	particular	cell	line)	—	bars	that	do	not	
have	common	letters	are	significantly	different,	p	<	0.01
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противоопухолевый эффект тимохинона 
и тимогидрохинона in vitro and in vivo
Цель: исследовать противоопухолевую активность тимохинона (TХ) и тимогидрохинона (TГХ) in vitro и in vivo. Материалы 
и методы: в экспериментах in vitro использовали линию клеток фибробластов мыши L929 и две линии опухолевых клеток 
мыши (плоскоклеточной карциномы SCC VII и фибросаркомы FsaR). По достижении монослоя, клетки инкубировали с 0,1 
или 0,01 мг/мл TХ или TГХ, после чего цитотоксический эффект определяли по включению кристаллического фиолетового. 
Противоопухолевый эффект 4-кратного внутриопухолевого введения TХ или TГХ в дозе 5 мг/кг in vivo в экспериментальных 
моделях FsaR и SCC VII определяли по кинетике опухолевого роста. Результаты: исследования in vitro показали, что TХ 
и TГХ обладают статистически значимой цитотоксической активностью (p < 0,01), причем таковая носит дозозависимый 
характер и в большей степени проявляется по отношению к линиям опухолевых клеток, чем фибробластов. Противоопу-
холевый эффект соединений статистически достоверный, ингибирование опухолевого роста достигало 52% (p < 0,05). 
Выводы: противоопухолевая активность ТГХ может быть повышена путем дальнейшего повышения дозы вещества.
Ключевые слова: тимохинон, тимогидрохинон, противоопухолевая активность, in vitro, in vivo, мыши.
